- Home
- INVA vs CGEM Comparison
INVA vs CGEM Comparison
Compare INVA & CGEM Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | INVA | CGEM |
|---|---|---|
| Founded | 1996 | 2016 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: Pharmaceutical Preparations | Biotechnology: Pharmaceutical Preparations |
| Sector | Health Care | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 1.7B | 1.4B |
| IPO Year | 2000 | 2020 |
Fundamental Metrics
Financial Performance| Metric | INVA | CGEM |
|---|---|---|
| Price | $21.34 | $21.69 |
| Analyst Decision | Buy | Strong Buy |
| Analyst Count | 5 | 8 |
| Target Price | ★ $32.80 | $30.13 |
| AVG Volume (30 Days) | 542.7K | ★ 684.6K |
| Earning Date | 05-07-2026 | 05-11-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 816.67 | N/A |
| EPS | ★ 1.25 | N/A |
| Revenue | ★ $217,217,000.00 | N/A |
| Revenue This Year | $8.95 | N/A |
| Revenue Next Year | $12.65 | $5.20 |
| P/E Ratio | $17.06 | ★ N/A |
| Revenue Growth | ★ 62.63 | N/A |
| 52 Week Low | $16.52 | $5.68 |
| 52 Week High | $25.15 | $23.19 |
Technical Indicators
Market Signals| Indicator | INVA | CGEM |
|---|---|---|
| Relative Strength Index (RSI) | 54.64 | 57.84 |
| Support Level | $21.42 | $11.87 |
| Resistance Level | $21.91 | $23.19 |
| Average True Range (ATR) | 0.35 | 0.95 |
| MACD | 0.08 | -0.15 |
| Stochastic Oscillator | 76.26 | 33.64 |
Price Performance
Historical ComparisonAbout INVA Innoviva Inc.
Innoviva Inc is a company with a portfolio of royalty healthcare assets. It has three primary sets of assets: a royalty portfolio, operating assets in critical care and infectious disease, and other strategic healthcare assets. Its product offering includes Relvar/Breo/Ellipta, Anoro, Trelegy, and others.
About CGEM Cullinan Oncology Inc.
Cullinan Therapeutics Inc is a clinical-stage biopharmaceutical company developing therapies for autoimmune diseases and cancer. Its development pipeline comprises the following drug candidates: CLN-978, a CD19xCD3 bispecific T cell engager that is being developed for autoimmune diseases; CLN-049, a FLT3xCD3 bispecific T cell engager being evaluated in an ongoing clinical trial in patients with relapsed/refractory acute myeloid leukemia (AML) or myelodysplastic syndrome (MDS); Velinotamig, a BCMAxCD3 bispecific T cell engager being developed to counter autoimmune diseases; and Zipalertinib, being developed as a treatment for non-small cell lung cancer. Additionally, the company is developing several preclinical programs in autoimmune diseases and oncology.